Repurposed quinacrine synergizes with cisplatin, reducing the effective dose required for treatment of head and neck squamous cell carcinoma.
Jennifer Bryant, Nikolaos Batis, Anna Clara Franke, Gabriella Clancey, Margaret Hartley, Gordon Ryan, Jill Brooks, Andrew D Southam, Nicholas Barnes, Joanna Parish, Sally Roberts, Farhat Khanim, Rachel Spruce, Hisham Mehanna
Oncotarget | Published : 2019
Despite highly toxic treatments, head and neck squamous cell carcinoma (HNSCC) have poor outcomes. There is an unmet need for more effective, less toxic therapies. Repurposing of clinically-approved drugs, with known safety profiles, may provide a time- and cost-effective approach to address this need. We have developed the AcceleraTED platform to repurpose drugs for HNSCC treatment; using in vitro assays (cell viability, clonogenic survival, apoptosis) and in vivo models (xenograft tumors in NOD/SCID/gamma mice). Screening a library of clinically-approved drugs identified the anti-malarial agent quinacrine as a candidate, which significantly reduced viability in a concentration dependent ma..View full abstract